PCCB

Across TCGA pan-cancer cohorts, PCCB Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PCCB data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher PCCB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCCB expression acts as an unfavorable survival marker.

SKCM, BLCA, and CESC are the cancer types where PCCB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	0.088	0.683	.001	17	view →
BLCA	OS	Median	III,IV	0.051	0.684	<.001	12	view →
CESC	OS	Median	II,III,IV	0.203	0.759	.021	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PCCB–SKCM (DFS)

Open the SKCM breakdown →